Unknown PHASE2 INTERVENTIONAL 1-arm NCT05130684

Neo-NTP-CRT for Locally Advanced ESCC (Neo-NTP-CRT)

Neoadjuvant Nivolumab Plus Paclitaxel/ Cisplatin- Chemo- Radiotherapy (Neo-NTP-CRT) Followed by Esophagectomy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)

Sponsor: National Taiwan University Hospital

Conditions Locally Advanced Esophageal Squamous Cell Carcinoma

Interventions Nivolumab

Updated 4 times since 2021 Last updated: Nov 22, 2021 Started: Feb 22, 2021 Primary completion: Mar 1, 2023 Completion: Mar 1, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Locally Advanced Esophageal Squamous Cell Carcinoma and is currently ongoing. National Taiwan University Hospital leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Apr 2024 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Dec 2021 — Apr 2024 [monthly]

Recruiting PHASE2

First recorded

Feb 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Taiwan University Hospital

Data source: National Taiwan University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Taipei, Taiwan